Jimbow K, Yamana K, Ishida O, Kawamura M, Ito Y, Maeda K
Gan To Kagaku Ryoho. 1987 Jan;14(1):152-8.
This study evaluated the clinical effect of rIFN-gamma for the treatment of lymphoma and melanoma of the skin by systemic intravenous and intralesional administration. By intravenous drip infusion, one of two cases of mycosis fungoides (stage IV) showed CR of skin lesions by administration of a total of 160 X 10(6) units, 4 or 8 X 10(6) units, every other day for 3 months. The remaining case was, however, in a state of PD. Intralesional administration of rIFN-gamma to six cases of cutaneous lymphoma, including three cases of mycosis fungoides, two cases of cutaneous T cell lymphoma, and one case of adult T cell lymphoma, resulted in three cases of CR, two cases of MR and one case of PD. In contrast, four cases of malignant melanoma, two of which received systemic administration and two intralesional administration, did not show any obvious clinical response, one showing PR and the other three PD. Histopathological examination of skin lesions before and after administration of rIFN-gamma indicated that the cutaneous lymphoma lesions were initially infiltrated by lymphocytes and macrophages, and that later on, they were free from tumor cells. Our study indicates that rIFN-gamma appears to provide a new modality for the treatment of cutaneous lymphoma by systemic and intralesional administration.
本研究通过全身静脉内和病灶内给药评估了重组干扰素-γ（rIFN-γ）治疗皮肤淋巴瘤和黑色素瘤的临床效果。通过静脉滴注，两例蕈样肉芽肿（IV期）患者中的一例，在每隔一天给予4或8×10⁶单位，共给药160×10⁶单位，持续3个月后，皮肤病变显示完全缓解（CR）。然而，另一例患者处于疾病进展（PD）状态。对6例皮肤淋巴瘤患者进行rIFN-γ病灶内给药，其中包括3例蕈样肉芽肿、2例皮肤T细胞淋巴瘤和1例成人T细胞淋巴瘤，结果3例完全缓解，2例部分缓解（MR），1例疾病进展。相比之下，4例恶性黑色素瘤患者，其中2例接受全身给药，2例接受病灶内给药，均未显示出明显的临床反应，1例显示部分缓解，另外3例疾病进展。对rIFN-γ给药前后的皮肤病变进行组织病理学检查表明，皮肤淋巴瘤病变最初被淋巴细胞和巨噬细胞浸润，随后肿瘤细胞消失。我们的研究表明，rIFN-γ似乎为通过全身和病灶内给药治疗皮肤淋巴瘤提供了一种新的治疗方式。
